We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+16.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$1.73B
AUM Growth
+$239M
Cap. Flow
+$39.4M
Cap. Flow %
2.27%
Top 10 Hldgs %
27.21%
Holding
142
New
9
Increased
33
Reduced
17
Closed
2

Top Buys

Rank Stock Value
1
HUM icon
Humana
HUM
+$27.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$20.9M
3
PCRX icon
Pacira BioSciences
PCRX
+$12.4M
4
AFAM
Almost Family Inc
AFAM
+$10.8M
5
OBSV
ObsEva SA Ordinary Shares
OBSV
+$10.3M

Top Sells

Rank Stock Value
1
AET
Aetna Inc
AET
+$27.7M
2
TSRO
TESARO, Inc.
TSRO
+$22.6M
3
ACRS icon
Aclaris Therapeutics
ACRS
+$12.3M
4
MEDP icon
Medpace
MEDP
+$4.87M
5
ARIA
Ariad Pharmaceuticals Inc
ARIA
+$3.11M

Sector Composition

Rank Sector Weight
1 Healthcare 82.21%
2 Financials 2.45%
3 Consumer Discretionary 0.63%
4 Industrials 0.41%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
76
DELISTED
Aimmune Therapeutics
AIMT
$6.37M 0.37%
293,000
– –
ACHN
77
DELISTED
Achillion Pharmaceuticals
ACHN
$6.32M 0.36%
1,500,000
+125,000
+9% +$519K
NBRV
78
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$6.3M 0.36%
2,100
– –
FPRX
79
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$5.96M 0.34%
165,000
+1,000
+0.6% +$44.1K
XENT
80
DELISTED
Intersect ENT, Inc
XENT
$5.92M 0.34%
345,000
– –
KYNB
81
Kyntra Bio
KYNB
$29.4M
$5.92M 0.34%
9,600
– –
CO
82
DELISTED
Global Cord Blood Corporation
CO
$5.86M 0.34%
880,000
– –
REGN icon
83
Regeneron Pharmaceuticals
REGN
$80.8B
$5.85M 0.34%
15,100
-4,400
-23% -$1.63M
SRPT icon
84
Sarepta Therapeutics
SRPT
$1.77B
$5.74M 0.33%
194,000
+2,100
+1% +$65K
GBT
85
DELISTED
Global Blood Therapeutics, Inc.
GBT
$5.53M 0.32%
150,000
+53,500
+55% +$1.35M
FOLD
86
DELISTED
Amicus Therapeutics
FOLD
$5.4M 0.31%
757,500
– –
LGND icon
87
Ligand Pharmaceuticals
LGND
$6.36B
$5.29M 0.31%
80,150
-32,060
-29% -$2.11M
KITE
88
DELISTED
Kite Pharma, Inc.
KITE
$5.26M 0.3%
67,000
-12,000
-15% -$742K
ADAP
89
DELISTED
Adaptimmune Therapeutics
ADAP
$4.82M 0.28%
875,000
+200,000
+30% +$875K
STE icon
90
Steris
STE
$23.1B
$4.51M 0.26%
65,000
– –
KDNY
91
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$4.46M 0.26%
83,000
– –
JUNO
92
DELISTED
Juno Therapeutics, Inc.
JUNO
$4.37M 0.25%
197,001
– –
NVDQ
93
DELISTED
Novadaq Technologies Inc.
NVDQ
$4.32M 0.25%
555,000
– –
AGN.PRA
94
DELISTED
Allergan plc
AGN.PRA
$4.24M 0.24%
5,000
– –
MGNX icon
95
MacroGenics
MGNX
$257M
$4.18M 0.24%
225,000
– –
SYRE icon
96
Spyre Therapeutics
SYRE
$9.25B
$3.9M 0.23%
20,964
– –
EXEL icon
97
Exelixis
EXEL
$13.4B
$3.79M 0.22%
175,000
– –
ALDR
98
DELISTED
Alder Biopharmaceuticals
ALDR
$3.79M 0.22%
182,000
– –
CORV
99
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$3.61M 0.21%
1,200,000
– –
CGEN icon
100
Compugen
CGEN
$228M
$3.55M 0.2%
825,000
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2017 Portfolio in Review

As of Q1 2017, Rock Springs Capital Management held 142 positions worth $1.73B, up 16% from $1.49B the previous quarter. Its ten largest holdings account for 27% of the portfolio.

Rock Springs Capital Management's Q1 2017 filing shows 9 new, 33 increased, 17 reduced and 2 closed positions. Its largest new stake was Humana: 132,500 shares worth $27.3M. The largest sale was Aetna Inc, an estimated $27.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, up from 81% a quarter earlier, followed by Financials and Consumer Discretionary.

  • Rock Springs Capital Management's largest Q1 2017 buy was Humana: 132,500 shares worth $27.3M.
  • Rock Springs Capital Management added most to Pacira BioSciences in Q1 2017, an estimated $12.4M increase.
  • Rock Springs Capital Management's biggest Q1 2017 reduction was Aetna Inc, cutting an estimated $27.7M.
  • Rock Springs Capital Management fully exited Medpace in Q1 2017, selling an estimated $4.87M.
  • Rock Springs Capital Management's ten largest holdings make up 27% of its $1.73B portfolio in Q1 2017.
  • Rock Springs Capital Management opened 9 new positions and closed 2 in Q1 2017.
  • Rock Springs Capital Management's portfolio value rose 16% quarter-over-quarter to $1.73B.

Based on Rock Springs Capital Management's 13F filing for Q1 2017, filed 15 May 2017.